NuCana Announces First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer
NuCana plc - American Depositary Shares (NCNA)
Last nucana plc - american depositary shares earnings: 3/10 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/ncna/historical
Company Research
Source: GlobeNewswire
EDINBURGH, United Kingdom, Nov. 15, 2017 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced the enrollment of the first patients in both the United States and the United Kingdom in its PRO-105 study evaluating single-agent Acelarin (NUC-1031) in patients with platinum-resistant ovarian cancer. Hugh Griffith, NuCana’s Chief Executive Officer, stated: “The initiation of this Phase 2 study of Acelarin in both the US and the UK is a major step in the expansion of the NuCana product pipeline and advances our strategy of rapidly developing our ProTides to benefit cancer patients globally. We are grateful to the patients and clinicians who are making this study possible.” The PRO-105 study will enroll up to 64 patients with platinum-resistant ovarian cancer who have relapsed following three or more prior lines of chemotherapy. Patients will receive Acelarin on day 1, 8 and 15 of a 28-day cycle and will be treated to progression. The primary endpoint of the study will be Objective
Show less
Read more
Impact Snapshot
Event Time:
NCNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NCNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NCNA alerts
High impacting NuCana plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
NCNA
News
- NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study [Yahoo! Finance]Yahoo! Finance
- NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical StudyGlobeNewswire
- NuCana plc (NASDAQ: NCNA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $4.00 price target on the stock.MarketBeat
- NuCana Announces Plan to Implement ADS Ratio Change [Yahoo! Finance]Yahoo! Finance
- NuCana Announces Plan to Implement ADS Ratio ChangeGlobeNewswire
NCNA
Sec Filings
- 4/9/24 - Form 6-K
- 3/27/24 - Form F-6
- 3/27/24 - Form 424B5
- NCNA's page on the SEC website